CJ to introduce intradermal BCGvaccine SSI in Korea

Published: 2004-02-27 06:58:00

Updated: 2004-02-27 06:58:00

CJ Corporation, a local maker of Capacin inj. (capreomycin) for treatment of tuberculosis infections, saidit has recently entered into an agreement with Denmark-based StatensSerumInstitute (SSI) for the exclusive distribution of BCGvaccine SSI with an aim to improve public health by eradicating t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK